Company overview
Ascelia Pharma is a biotech company specializing in the development and commercialization of novel drugs for orphan oncology indications, addressing unmet medical needs in rare cancers. Their lead candidate, Orviglance, is a Phase 3 liver-specific MRI contrast agent for detecting metastases in patients unable to use gadolinium-based agents. Oncoral, an oral irinotecan formulation, has completed Phase 1 trials for advanced gastric cancer and is advancing to Phase 2, with active pursuit of partnerships for clinical development and global commercialization.
ASCELIA is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include ascelia pharma, orphan oncology, orviglance, oncoral, drug development.
Structured facts
- Website
- https://www.ascelia.com/
- Markets served
- United States & Americas
- Keywords
- ascelia pharma, orphan oncology, orviglance, oncoral, drug development
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are Ascelia Pharma's key drug candidates and development stages?
- Orviglance is in Phase 3 for liver MRI contrast in oncology patients contraindicated for gadolinium agents. Oncoral, an oral irinotecan for gastric cancer, completed Phase 1 and plans Phase 2 studies.
- What partnering opportunities does Ascelia offer?
- Ascelia seeks commercialization partners for Orviglance in the US and regions, and clinical development partners for Oncoral. They pursue collaborations in orphan oncology from universities to biotech firms.
- Where is Ascelia Pharma based and what is their therapeutic focus?
- Headquartered in Malmö, Sweden, Ascelia focuses on orphan oncology drugs for rare cancers, developing treatments with clear regulatory pathways.
Related editorial coverage
- Biotech’s coming of age: AI, capital efficiency and China reshape the field
- Global hematology trials keep research patient-centered and regionally relevant
- America's Innovation Engine: Small and Mid-Sized Biotechs Drive U.S. Clinical Trials, FDA Filings
- Otsuka kidney drug data and Pfizer AI deal: Biopharma deal tracker
- FDA Extends Comment Period for Real-Time Clinical Trials Pilot, AI Use in Studies
- SGS Expands Bioanalytical Testing Capabilities in North America with Acquisition of CMIC, INC.
Explore lab tools and QA/QC resources for R&D teams.
